Zydus plans to complete late-stage trials for ZyCoV-D by February or March and could produce up to 100 million doses a year initially, the company’s chairman told Reuters last month.
India reported a daily jump of more than 50,000 coronavirus infections for the seventh straight day on Wednesday.Total cases now stand at 1.91 million, the third biggest, after the United States and Brazil
Category:
Disaster & Management
Latest
90% of recovered COVID-19 patients in Wuhan suffering from lung damage:report
According to the first phase results, 90 per cent of the patients” lungs are still in a damaged state, which means their lungs ventilation and gas exchange functions have not recovered to the level of healthy people, state-run Global Times reported.
Some recovered patients have to rely on oxygen machines even three months after being discharged from the hospital, Liang Tengxiao, a doctor from the Dongzhimen Hospital, Beijing University of Chinese Medicine, was quoted as saying by the report.
Indian pharma majors race ahead to launch affordable drugs for Covid-19 treatment
Drug major Cipla is working with government agencies to develop a treatment for COVID-19 while ramping up the production of various life saving essential drugs, according to company’s chairman YK Hamied.
Drug firm BDR Pharmaceuticals on Wednesday said it has launched its antiviral drug Favipiravir for the treatment of COVID-19 patients in India at a price of Rs 63 per tablet.
Lupin on Wednesday announced the launch of its Favipiravir drug under the brand name ‘Covihalt’ for the treatment patients with mild to moderate COVID-19 symptoms at Rs 49 per tablet in India.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.